| Literature DB >> 31238124 |
Raymond Pranata1, Emir Yonas2, Rachel Vania3, Ian Huang4.
Abstract
BACKGROUND: Controversies surrounded the management of asymptomatic Brugada syndrome. Prognostication using electrophysiology study (EPS) is disputable. Non-invasive parameters may be a valuable additional tool for risk stratification. We aim to evaluate the use markers of ventricular repolarization including Tpeak-to-Tend (TpTe), Tpe Dispersion, TpTe/QT ratio, and QTc interval as additional non-invasive electrocardiography parameters for predicting ventricular tachycardia/fibrillation in patients with Brugada syndrome.Entities:
Keywords: Brugada syndrome; QTc interval; TpTe interval; TpTe interval/QT ratio; Tpe dispersion
Year: 2019 PMID: 31238124 PMCID: PMC6904796 DOI: 10.1016/j.ipej.2019.06.003
Source DB: PubMed Journal: Indian Pacing Electrophysiol J ISSN: 0972-6292
Fig. 1Study flow diagram.
Summary of the key findings of this systematic review.
| Study | Study Design | Samples | Subjects | Outcome of Interest | Results |
|---|---|---|---|---|---|
| Morita 2018 | Case-Control | 62 | Brugada-type ECG | Initial VF | TpTe → OR of difference Tpe interval (V1) ≥ +10 m s: 11.0, CI: 2.6–46.1, p = 0.001. Mean 108 ± 33 m s vs 78 ± 18 m s; p < 0.01. Tpe Dispersion → No Data TpTe/QT ratio → No Data Max QTc → Mean 411 ± 52 m s vs 371 ± 33 m s; p < 0.01. |
| Morita 2017 | Retrospective Cohort | 471 | Brugada Syndrome | VF (but also included syncope) | TpTe → TpTe V2 ≥ 95 → HR 3.03 1.26–9.01 0.0143. Mean 86 ± 25 m s vs 81 ± 23 m s; p = 0.04. Tpe Dispersion → No Data TpTe/QT ratio → No Data Max QT (not corrected) → Mean 399 ± 41 m s vs 385 ± 34 m s; p < 0.0003. |
| Zumhagen 2016 | Case-Control | 78 | Brugada Syndrome | VT/VF/Aborted SCD | TpTe → ≥ 77 m s, 63.6% & 74.1%; AUC 0.675. Mean 87 ± 30 m s vs 71 ± 21 m s Tpe Dispersion → No Data TpTe/QT ratio → ≥ 0.205, 72.7% & 68.5%; AUC 0.673. Mean 0.24 ± 0.09 m s vs 0.19 ± 0.05 m s Max QTc → not statistically significant |
| Maury 2015 | Case-Control | 325 | Brugada Syndrome | SCF/Appropriate ICD Shocks | TpTe → Max Tpe >100 m s OR of 9.61 (95% CI 3.13–9.41) (p < 0.0001). Sensitivity 84% & Specificity 68%, PPV 19%, NPV 98%. Mean 85 ± 18 m s vs 67 ± 22 m s; p < 0.001 Tpe Dispersion → Mean 47 ± 27 m s vs 30 ± 17 m s; p = 0.005 TpTe/QT ratio → Mean 0.21 ± 0.04 vs 0.17 ± 0.05; p < 0.0001 Max QTc → No Data AUROC: 0.789 |
| Mugnai 2017 | Cohort | 448 | Brugada Syndrome | VT/VF/SCD/Appropriate ICD Shocks | TpTe → Not statistically significant Tpe Dispersion → Not statistically significant TpTe/QT ratio → Not statistically significant Max QTc → not statistically significant |
| Kawazoe 2016 | Case-Control | 143 | Brugada Syndrome | VF | TpTe → mean 124 ± 33 m s vs 104 ± 22 m s; p = 0.001 Tpe Dispersion → Mean 59 ± 29 m s vs 35 ± 23 m s; p = 0.0001. Tpe Dispersion was an independent predictor of VF, adjusted OR 1.069 (1.03–1 .10), p = 0.001. TpTe/QT ratio → No Data. Max QTc → Mean 401 ± 32 m s vs 386 ± 37 m s; p = 0.33. Tpe Dispersion AUROC 0.869 |
| Letsas 2010 | Case-Control | 23 | Brugada Syndrome | VT/VF Inducibility | TpTe → TpTe V2 (88.82 ± 15.70 m s vs. 78.33 ± 4.08 m s, P = 0.02) and V6 (mean 76.33 ± 10.08 m s vs 66.66 ± 5.16 m s, P = 0.04). Tpe Dispersion → Not statistically significant. TpTe/QT ratio → Greater Tpeak–Tend/QT ratio in lead V6 (0.214 + 0.028 vs 0.180 + 0.014, P = 0.009). Max QTc → Not statistically significant. |
| Hevia 2006 | Cohort | 29 | Brugada Syndrome | VT/VF | TpTe → TpTe Cut-off point >100 m s; Sensitivity 77.8% & specificity 70%; AUC 0.7861. TpTe was significantly prolonged in patients with recurrences versus patients without events (mean 104.4 m s vs 87.4 m s; p = 0.006). Tpe Dispersion → Tp-e dispersion Cut-off point >20 m s; Sensitivity 66.7% & Specificity 90%; AUC 0.7722. Tp-e dispersion was significantly prolonged in patients with recurrences versus patients without events (mean 35.6 m s vs 23.2 m s; p = 0.03). TpTe/QT ratio → No Data Max QTc → QTc >460 m s in V2, was associated with VT/VF recurrence; p = 0.03 |
| Calo 2016 | Cohort | 347 | Brugada Syndrome | VF/SCD | TpTe → TpTe HR 1.028 [1.013–1.042]; <0.0001 (cut-off unknown). Mean 90 ± 25 m s vs 72 ± 22 m s; p = 0.044. Tpe Dispersion → No Data TpTe/QT ratio → No Data Max QTc → Not statistically significant |
| Juntilla 2008 | Cross-Section | 200 | Brugada Syndrome | Syncope/VT/VF/SCD | TpTe → Not statistically significant Tpe Dispersion → No Data TpTe/QT ratio → No Data Max QTc → Not statistically significant |
Description: TpTe = Tpeak-Tend interval; SCD=Sudden Cardiac Death; ICD=Implantable Cardioverter Defibrillator; VF=Ventricular Fibrillation; VT=Ventricular Tachycardia. Results of the systematic review of the role of Tpeak-Tend, Tpeak-Tend/QT ratio, and Tpe Dispersion as Additional Non-Invasive Electrocardiography Parameters for Predicting Ventricular Tachycardia/Fibrillation in Patients with Brugada Syndrome.
Fig. 2Mean Difference of Tpeak-Tend interval and Max QTc interval between VT/VF/AT/Aborted SCD group and those without.
Mean Difference of Tpeak-Tend interval (Fig. 2A) and Max QTc (Fig. 2B) interval between VT/VF/AT/Aborted SCD group and those without. Fig. 2C showed a heterogeneity of 0% after removal of Morita 2018 et al. study upon sensitivity analysis. Description: AT = Appropriate ICD Shock, SCD=Sudden Cardiac Death, VF=Ventricular Fibrillation, VT=Ventricular Tachycardia.
Fig. 3Mean Difference of Tpe Dispersion and TpTe/QT ratio between VT/VF/AT/Aborted SCD group and those without.
Mean difference of Tpe Dispersion (Fig. 3A) and TpTe/QT ratio (Fig. 3B) between VT/VF/AT/Aborted SCD group and those without. Description: AT = Appropriate ICD Shock, SCD=Sudden Cardiac Death, VF=Ventricular Fibrillation, VT=Ventricular Tachycardia. The fixed-effect model yields a statistically significant result, but not the random-effect model.